AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients
2020-05-01 · SynDevRx, Inc. · original syndevrx.com ↗
AACR 2020: SynDevRx Selected to Present the Results from its Phase 1 Study of SDX-7320 in Late-Stage Cancer Patients SynDevRx recently completed a Phase 1 study in late-stage cancer patients with a variety of solid tumors. The initial results from the clinical study were selected by AACR for presentation by one of the Principle Investigators – Dr. Monica Mita, MD. Dr. Mita is a Professor of Medicine, Co-Director, Experimental Therapeutics Program at Cedars-Sinai Medical Center Los Angeles, and also has a specialty practice in breast cancer. Final results from the Phase 1 study, “ A Dose Escalation Study of SDX-7320 in Patients With Advanced Refractory or Late-Stage Solid Tumors ” are being prepared for submission to the FDA. Presented by Monica Mita, MD Download the Presentation here. Leave a Reply Cancel reply You must be logged in to post a comment.
The release as fetched from its publisher. syndevrx.com ↗